Get the composition of our in-house portfolios

All portfolios and performance
Portfolio Ref: EQ3525LS3W
Performance in the last:
Follow this Portfolio
1D 0.0 %
1W -1.1 %
2W -1.5 %
1M 5.0 %
3M 9.0 %
6M 23.6 %
9M 24.8 %
1Y -26.0 %
Alpha
-34.6%
Beta
0.45
sharpe-R
-0.51
Benchmark
SP500 (SPDR S&P 500 ETF Trust)
sharpe-R Benchmark
1.8
The portfolio metrics Alpha, Beta and Sharpe Ratio are computed using a risk free rate of 0%.
Other Information
Calculation Frequency Daily
Latest Valuation Time 2025-02-18 07:01:09
Launch Date 2023-01-01 00:00:00
First Valuation Date 2021-01-01 00:00:00
Max. DrawDown -50.18%
Max. DrawDown Benchmark -8.41%

This Long-Short strategy aims to find promising assets to invest in for a maximum holding period of 3 Weeks in the Equity asset class. This portfolio focuses only on companies in the Health Care sector. The maximum number of assets that can be allocated in this strategy is 25.

The assets selection in this portfolio is based on: Macro-Pattern Mix St..
Please note that all model portfolios assume that the entry price for each trade is the previous close price.

For Long-Short model portfolios, the short-selling costs (asset borrowing costs) are not taken into account. This assumption is likely unrealistic, and it is important to understand the short-selling process before employing this type of strategy.

Portfolio Performance against the market Benchmark

Try Our Peformance Checker Tool

Risk Level
3
Difficulty Level
4

Do you want to invest in this strategy ?

Follow the portfolio and you will get notified for every change in the composition of the portfolio

Current Portfolio Composition

Asset Action Weight PnL
RGNX REGENXBIO Inc. Buy 8.06% -9.54%
UTMD Utah Medical Products, Inc. Sell -3.27% 0.42%
AADI Aadi Bioscience, Inc. Sell -2.94% 10.38%
CARA Cara Therapeutics, Inc. Sell -5.27% -7.44%
ANGO AngioDynamics, Inc. Sell -3.28% 6.34%
The percentage of cash held in the portfolio is: 106.71%
** The description of each asset is available Here

The latest 5 Compositions change

2025-02-14 00:00:00 : Portfolio change date
Asset Action Weight PnL
RGNX REGENXBIO Inc. Buy 8.12% -9.29%
UTMD Utah Medical Products, Inc. Sell -3.33% -0.75%
AADI Aadi Bioscience, Inc. Sell -2.98% 9.69%
CARA Cara Therapeutics, Inc. Sell -5.71% -15.7%
ANGO AngioDynamics, Inc. Sell -3.36% 4.62%
The percentage of cash held in the portfolio is: 107.25%
New Assets Added
None
Assets Removed
Asset Action Perf %
HROW Buy All 1.18%
Assets Rebalanced
None
2025-02-13 00:00:00 : Portfolio change date
Asset Action Weight PnL
RGNX REGENXBIO Inc. Buy 7.95% -10.78%
HROW Harrow Health, Inc. Sell -4.63% 7.28%
UTMD Utah Medical Products, Inc. Sell -3.24% 1.26%
AADI Aadi Bioscience, Inc. Sell -3.05% 7.27%
CARA Cara Therapeutics, Inc. Sell -5.32% -8.47%
ANGO AngioDynamics, Inc. Sell -3.32% 5.25%
The percentage of cash held in the portfolio is: 111.61%
New Assets Added
None
Assets Removed
Asset Action Perf %
FGEN Buy All 9.52%
Assets Rebalanced
None
2025-02-11 00:00:00 : Portfolio change date
Asset Action Weight PnL
RGNX REGENXBIO Inc. Buy 8.69% -2.23%
FGEN FibroGen, Inc. Sell -4.28% 1.19%
HROW Harrow Health, Inc. Sell -4.94% 0.9%
UTMD Utah Medical Products, Inc. Sell -3.23% 1.44%
AADI Aadi Bioscience, Inc. Sell -3.02% 7.96%
CARA Cara Therapeutics, Inc. Sell -5.1% -4.13%
ANGO AngioDynamics, Inc. Sell -3.44% 1.72%
The percentage of cash held in the portfolio is: 115.31%
New Assets Added
None
Assets Removed
Asset Action Perf %
AGEN Sell All -15.67%
Assets Rebalanced
None
2025-02-10 00:00:00 : Portfolio change date
Asset Action Weight PnL
AGEN Agenus Inc. Buy 6.94% -8.62%
RGNX REGENXBIO Inc. Buy 8.96% 1.73%
FGEN FibroGen, Inc. Sell -4.29% 0.2%
HROW Harrow Health, Inc. Sell -4.74% 3.96%
UTMD Utah Medical Products, Inc. Sell -3.17% 2.37%
AADI Aadi Bioscience, Inc. Sell -3.11% 4.15%
CARA Cara Therapeutics, Inc. Sell -5.01% -3.31%
ANGO AngioDynamics, Inc. Sell -3.47% 0%
The percentage of cash held in the portfolio is: 107.9%
New Assets Added
None
Assets Removed
Asset Action Perf %
BLFS Sell All -7.77%
Assets Rebalanced
None
2025-02-07 00:00:00 : Portfolio change date
Asset Action Weight PnL
AGEN Agenus Inc. Buy 7.37% -2.35%
BLFS BioLife Solutions, Inc. Buy 9.6% -7.46%
RGNX REGENXBIO Inc. Buy 9.15% 4.46%
FGEN FibroGen, Inc. Sell -4.24% 0.79%
HROW Harrow Health, Inc. Sell -4.72% 3.87%
UTMD Utah Medical Products, Inc. Sell -3.16% 2.3%
AADI Aadi Bioscience, Inc. Sell -3.16% 2.08%
CARA Cara Therapeutics, Inc. Sell -5.11% -5.79%
ANGO AngioDynamics, Inc. Sell -3.47% -0.54%
The percentage of cash held in the portfolio is: 97.72%
New Assets Added
None
Assets Removed
Asset Action Perf %
ORGO Sell All 6.61%
Assets Rebalanced
None
2025-02-06 00:00:00 : Portfolio change date
Asset Action Weight PnL
ORGO Organogenesis Holdings Inc. Buy 7.74% 8.11%
AGEN Agenus Inc. Buy 7.64% 1.83%
BLFS BioLife Solutions, Inc. Buy 9.74% -5.58%
RGNX REGENXBIO Inc. Buy 9.09% 4.46%
FGEN FibroGen, Inc. Sell -4.27% -0.6%
HROW Harrow Health, Inc. Sell -4.67% 4.34%
UTMD Utah Medical Products, Inc. Sell -3.14% 2.14%
AADI Aadi Bioscience, Inc. Sell -3.22% -0.35%
CARA Cara Therapeutics, Inc. Sell -4.99% -4.13%
ANGO AngioDynamics, Inc. Sell -3.38% 1.36%
The percentage of cash held in the portfolio is: 89.47%
New Assets Added
None
Assets Removed
Asset Action Perf %
MD Sell All -0.14%
MDXG Sell All -3.17%
AXSM Sell All 21.6%
CERS Sell All 1.62%
ATXS Sell All -2.31%
DNLI Sell All 9.72%
NVRO Sell All 18.4%
LGND Sell All 6.37%
Assets Rebalanced
None
2025-02-05 00:00:00 : Portfolio change date
Asset Action Weight PnL
MD Pediatrix Medical Group, Inc. Buy 7.2% -0.64%
MDXG MiMedx Group, Inc. Buy 7.03% -3.06%
AXSM Axsome Therapeutics, Inc. Buy 8.72% 20.45%
CERS Cerus Corporation Buy 6.14% 0.54%
ATXS Astria Therapeutics, Inc. Buy 7% -3.47%
DNLI Denali Therapeutics Inc. Buy 7.59% 6.93%
NVRO Nevro Corp. Buy 7.01% 20.99%
LGND Ligand Pharmaceuticals Incorporated Buy 6.72% 6.33%
ORGO Organogenesis Holdings Inc. Buy 7.54% 4.5%
AGEN Agenus Inc. Buy 6.91% -8.62%
BLFS BioLife Solutions, Inc. Buy 9.67% -6.96%
RGNX REGENXBIO Inc. Buy 9.17% 4.46%
FGEN FibroGen, Inc. Sell -3.93% 8.1%
HROW Harrow Health, Inc. Sell -4.7% 4.52%
UTMD Utah Medical Products, Inc. Sell -3.17% 2.17%
AADI Aadi Bioscience, Inc. Sell -3.06% 5.54%
CARA Cara Therapeutics, Inc. Sell -4.91% -1.45%
ANGO AngioDynamics, Inc. Sell -3.44% 0.54%
The percentage of cash held in the portfolio is: 32.5%
New Assets Added
None
Assets Removed
Asset Action Perf %
GERN Buy All 1.02%
MDRX Buy All 47.11%
ACRS Sell All 0.4%
NUTX Sell All 52.16%
Assets Rebalanced
None
2025-02-04 00:00:00 : Portfolio change date
Asset Action Weight PnL
ACRS Aclaris Therapeutics, Inc. Buy 7.43% -4%
NUTX Nutex Health Inc. Buy 8.31% 53.16%
MD Pediatrix Medical Group, Inc. Buy 7.38% -0.57%
MDXG MiMedx Group, Inc. Buy 7.18% -3.17%
AXSM Axsome Therapeutics, Inc. Buy 8.49% 14.59%
CERS Cerus Corporation Buy 6.09% -2.7%
ATXS Astria Therapeutics, Inc. Buy 7.08% -4.62%
DNLI Denali Therapeutics Inc. Buy 7.38% 1.58%
NVRO Nevro Corp. Buy 6.97% 17.45%
LGND Ligand Pharmaceuticals Incorporated Buy 6.73% 4.06%
ORGO Organogenesis Holdings Inc. Buy 7.56% 2.4%
AGEN Agenus Inc. Buy 7.1% -8.36%
BLFS BioLife Solutions, Inc. Buy 10.01% -5.94%
RGNX REGENXBIO Inc. Buy 8.71% -3.1%
GERN Geron Corporation Sell -3.66% 3.06%
MDRX Allscripts Healthcare Solutions, Inc. Sell -2.75% 44.44%
FGEN FibroGen, Inc. Sell -4.14% 5.56%
HROW Harrow Health, Inc. Sell -4.65% 7.62%
UTMD Utah Medical Products, Inc. Sell -3.24% 2.27%
AADI Aadi Bioscience, Inc. Sell -3.14% 5.19%
CARA Cara Therapeutics, Inc. Sell -4.89% 1.24%
ANGO AngioDynamics, Inc. Sell -3.54% 0%
The percentage of cash held in the portfolio is: 23.59%
New Assets Added
  • ANGO
Assets Removed
Asset Action Perf %
AVXL Buy All 18.1%
INSM Sell All 12.98%
AXGN Sell All -1.81%
SIGA Sell All -9.55%
Assets Rebalanced
None
2025-02-03 00:00:00 : Portfolio change date
Asset Action Weight PnL
INSM Insmed Incorporated Buy 6.88% 11.1%
AXGN AxoGen, Inc. Buy 6.72% -0.22%
ACRS Aclaris Therapeutics, Inc. Buy 7.5% -0.8%
NUTX Nutex Health Inc. Buy 7.89% 48.84%
MD Pediatrix Medical Group, Inc. Buy 7.23% -0.14%
MDXG MiMedx Group, Inc. Buy 7.14% -1.36%
AXSM Axsome Therapeutics, Inc. Buy 8.21% 13.56%
CERS Cerus Corporation Buy 6.17% 1.08%
ATXS Astria Therapeutics, Inc. Buy 7.31% 0.9%
DNLI Denali Therapeutics Inc. Buy 7.69% 8.37%
NVRO Nevro Corp. Buy 6.92% 19.58%
LGND Ligand Pharmaceuticals Incorporated Buy 6.68% 5.69%
ORGO Organogenesis Holdings Inc. Buy 7.97% 10.51%
AGEN Agenus Inc. Buy 7.5% -0.78%
SIGA SIGA Technologies, Inc. Buy 7.39% -6.42%
BLFS BioLife Solutions, Inc. Buy 10.03% -3.5%
RGNX REGENXBIO Inc. Buy 8.77% 0%
AVXL Anavex Life Sciences Corp. Sell -3.4% 12.13%
GERN Geron Corporation Sell -3.59% 2.38%
MDRX Allscripts Healthcare Solutions, Inc. Sell -2.93% 39.33%
FGEN FibroGen, Inc. Sell -4.11% 3.97%
HROW Harrow Health, Inc. Sell -4.68% 4.86%
UTMD Utah Medical Products, Inc. Sell -3.23% 0.13%
AADI Aadi Bioscience, Inc. Sell -3.22% 0.35%
CARA Cara Therapeutics, Inc. Sell -4.83% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • CARA
  • RGNX
Assets Removed
Asset Action Perf %
VKTX Buy All 16.69%
TGTX Sell All -0.69%
Assets Rebalanced
None
2025-01-30 00:00:00 : Portfolio change date
Asset Action Weight PnL
INSM Insmed Incorporated Buy 7.08% 13.16%
AXGN AxoGen, Inc. Buy 6.82% 0.33%
ACRS Aclaris Therapeutics, Inc. Buy 7.21% -5.6%
NUTX Nutex Health Inc. Buy 7.49% 39.94%
MD Pediatrix Medical Group, Inc. Buy 7.42% 1.36%
MDXG MiMedx Group, Inc. Buy 7.51% 2.61%
AXSM Axsome Therapeutics, Inc. Buy 8.2% 12.15%
CERS Cerus Corporation Buy 6.47% 4.86%
ATXS Astria Therapeutics, Inc. Buy 7.01% -4.24%
DNLI Denali Therapeutics Inc. Buy 7.8% 8.88%
NVRO Nevro Corp. Buy 6.98% 19.34%
LGND Ligand Pharmaceuticals Incorporated Buy 6.88% 7.83%
ORGO Organogenesis Holdings Inc. Buy 8.32% 14.11%
AGEN Agenus Inc. Buy 7.2% -5.74%
SIGA SIGA Technologies, Inc. Buy 7.82% -2.03%
TGTX TG Therapeutics, Inc. Buy 7.3% 4.54%
BLFS BioLife Solutions, Inc. Buy 10.5% 0%
VKTX Viking Therapeutics, Inc. Sell -2.99% 14.96%
AVXL Anavex Life Sciences Corp. Sell -3.6% 8.06%
GERN Geron Corporation Sell -3.66% 1.7%
MDRX Allscripts Healthcare Solutions, Inc. Sell -4.13% 15.44%
FGEN FibroGen, Inc. Sell -4.12% 4.76%
HROW Harrow Health, Inc. Sell -4.98% -0.19%
UTMD Utah Medical Products, Inc. Sell -3.27% 0%
AADI Aadi Bioscience, Inc. Sell -3.27% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • UTMD
  • AADI
  • BLFS
Assets Removed
Asset Action Perf %
ORMP Buy All 5.46%
AORT Sell All 3.27%
Assets Rebalanced
None
2025-01-29 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 7.29% 2.68%
INSM Insmed Incorporated Buy 7.2% 13.83%
AXGN AxoGen, Inc. Buy 6.94% 0.88%
ACRS Aclaris Therapeutics, Inc. Buy 7.38% -4.4%
NUTX Nutex Health Inc. Buy 7.24% 33.72%
MD Pediatrix Medical Group, Inc. Buy 7.64% 3.29%
MDXG MiMedx Group, Inc. Buy 7.6% 2.72%
AXSM Axsome Therapeutics, Inc. Buy 8.08% 9.29%
CERS Cerus Corporation Buy 7.15% 14.59%
ATXS Astria Therapeutics, Inc. Buy 7.11% -3.85%
DNLI Denali Therapeutics Inc. Buy 7.92% 9.3%
NVRO Nevro Corp. Buy 6.96% 17.69%
LGND Ligand Pharmaceuticals Incorporated Buy 6.91% 7.1%
ORGO Organogenesis Holdings Inc. Buy 7.88% 6.91%
AGEN Agenus Inc. Buy 7.18% -7.05%
SIGA SIGA Technologies, Inc. Buy 7.83% -2.97%
TGTX TG Therapeutics, Inc. Buy 7.39% 4.79%
ORMP Oramed Pharmaceuticals Inc. Sell -3.3% 5.46%
VKTX Viking Therapeutics, Inc. Sell -3.1% 12.69%
AVXL Anavex Life Sciences Corp. Sell -3.71% 6.07%
GERN Geron Corporation Sell -3.84% -2.04%
MDRX Allscripts Healthcare Solutions, Inc. Sell -4.39% 11.11%
FGEN FibroGen, Inc. Sell -4.25% 2.78%
HROW Harrow Health, Inc. Sell -5.09% -1.27%
The percentage of cash held in the portfolio is: 2%
New Assets Added
None
Assets Removed
Asset Action Perf %
FATE Buy All 25.71%
Assets Rebalanced
Asset Action Weight
AXGN Sell -0.84%
TGTX Sell -5.51%
AXSM Buy 0.24%
DNLI Buy 0.36%
SIGA Buy 0.47%
ORGO Buy 1.03%
2025-01-28 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 7.22% 1.36%
AXGN AxoGen, Inc. Buy 7.6% -1.75%
INSM Insmed Incorporated Buy 7.14% 12.62%
ACRS Aclaris Therapeutics, Inc. Buy 7.59% -2%
NUTX Nutex Health Inc. Buy 6.87% 26.44%
MD Pediatrix Medical Group, Inc. Buy 7.78% 4.86%
MDXG MiMedx Group, Inc. Buy 7.33% -1.25%
ATXS Astria Therapeutics, Inc. Buy 7.19% -3.21%
AXSM Axsome Therapeutics, Inc. Buy 7.19% 9.54%
LGND Ligand Pharmaceuticals Incorporated Buy 6.88% 6.35%
DNLI Denali Therapeutics Inc. Buy 6.97% 7.86%
CERS Cerus Corporation Buy 7.27% 16.22%
NVRO Nevro Corp. Buy 7.01% 18.16%
ORGO Organogenesis Holdings Inc. Buy 7.21% 12.31%
AGEN Agenus Inc. Buy 7.28% -6.01%
SIGA SIGA Technologies, Inc. Buy 7.1% -0.78%
TGTX TG Therapeutics, Inc. Buy 12.35% 0%
FATE Fate Therapeutics, Inc. Sell -2.75% 21.71%
ORMP Oramed Pharmaceuticals Inc. Sell -3.3% 5.88%
VKTX Viking Therapeutics, Inc. Sell -3.03% 14.88%
AVXL Anavex Life Sciences Corp. Sell -3.69% 6.92%
GERN Geron Corporation Sell -3.8% -0.68%
MDRX Allscripts Healthcare Solutions, Inc. Sell -4.14% 16.33%
FGEN FibroGen, Inc. Sell -4.24% 3.17%
HROW Harrow Health, Inc. Sell -5.04% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • HROW
  • TGTX
Assets Removed
Asset Action Perf %
ESPR Sell All -14.96%
Assets Rebalanced
None
2025-01-27 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 7.29% 1.42%
ESPR Esperion Therapeutics, Inc. Buy 7.81% -10.26%
AXGN AxoGen, Inc. Buy 7.76% -0.6%
INSM Insmed Incorporated Buy 7.29% 13.85%
ACRS Aclaris Therapeutics, Inc. Buy 7.85% 0.4%
NUTX Nutex Health Inc. Buy 7.29% 32.94%
MD Pediatrix Medical Group, Inc. Buy 7.66% 2.29%
MDXG MiMedx Group, Inc. Buy 7.47% -0.34%
ATXS Astria Therapeutics, Inc. Buy 7.13% -4.88%
AXSM Axsome Therapeutics, Inc. Buy 7.29% 9.98%
LGND Ligand Pharmaceuticals Incorporated Buy 6.81% 4.31%
DNLI Denali Therapeutics Inc. Buy 6.74% 3.35%
CERS Cerus Corporation Buy 6.73% 6.49%
NVRO Nevro Corp. Buy 7.29% 21.7%
ORGO Organogenesis Holdings Inc. Buy 6.93% 6.91%
AGEN Agenus Inc. Buy 7.29% -6.79%
SIGA SIGA Technologies, Inc. Buy 7.29% 0.94%
FATE Fate Therapeutics, Inc. Sell -2.69% 24%
ORMP Oramed Pharmaceuticals Inc. Sell -3.37% 4.62%
VKTX Viking Therapeutics, Inc. Sell -3.16% 12.24%
AVXL Anavex Life Sciences Corp. Sell -3.98% 0.57%
GERN Geron Corporation Sell -3.9% -2.38%
MDRX Allscripts Healthcare Solutions, Inc. Sell -4.33% 13.33%
FGEN FibroGen, Inc. Sell -4.47% -0.99%
The percentage of cash held in the portfolio is: 2%
New Assets Added
None
Assets Removed
Asset Action Perf %
TGTX Buy All -11.64%
Assets Rebalanced
Asset Action Weight
DNLI Sell -1.01%
LGND Sell -1%
CERS Sell -1.25%
AXSM Sell -0.95%
INSM Sell -1.6%
NVRO Sell -1.83%
NUTX Sell -3.11%
ESPR Buy 0.93%
AORT Buy 1.02%
AGEN Buy 1.34%
SIGA Buy 2.95%
2025-01-23 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 6.34% 1.82%
ESPR Esperion Therapeutics, Inc. Buy 6.71% -5.98%
AXGN AxoGen, Inc. Buy 8.14% 3.51%
INSM Insmed Incorporated Buy 8.95% 13.81%
NUTX Nutex Health Inc. Buy 9.38% 19.09%
ACRS Aclaris Therapeutics, Inc. Buy 8.19% 4%
MD Pediatrix Medical Group, Inc. Buy 7.58% 0.5%
MDXG MiMedx Group, Inc. Buy 7.69% 1.93%
NVRO Nevro Corp. Buy 8.72% 15.57%
LGND Ligand Pharmaceuticals Incorporated Buy 7.93% 5.06%
AXSM Axsome Therapeutics, Inc. Buy 8.23% 9.09%
CERS Cerus Corporation Buy 7.38% -2.16%
DNLI Denali Therapeutics Inc. Buy 8.18% 8.42%
ATXS Astria Therapeutics, Inc. Buy 7.26% -3.72%
ORGO Organogenesis Holdings Inc. Buy 6.86% 5.11%
AGEN Agenus Inc. Buy 6.14% -4.44%
SIGA SIGA Technologies, Inc. Buy 4.33% 0%
TGTX TG Therapeutics, Inc. Sell -3.74% -4.07%
FATE Fate Therapeutics, Inc. Sell -2.73% 23.43%
ORMP Oramed Pharmaceuticals Inc. Sell -3.46% 2.94%
VKTX Viking Therapeutics, Inc. Sell -3.14% 13.38%
AVXL Anavex Life Sciences Corp. Sell -3.82% 5.31%
GERN Geron Corporation Sell -3.9% -1.7%
MDRX Allscripts Healthcare Solutions, Inc. Sell -4.76% 5.33%
FGEN FibroGen, Inc. Sell -4.45% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • FGEN
  • SIGA
Assets Removed
Asset Action Perf %
EBS Buy All -15.52%
BLUE Sell All -20.97%
Assets Rebalanced
None
2025-01-22 00:00:00 : Portfolio change date
Asset Action Weight PnL
BLUE bluebird bio, Inc. Buy 4.7% -17.94%
AORT Artivion, Inc. Buy 6.5% 4.5%
ESPR Esperion Therapeutics, Inc. Buy 6.55% -8.12%
AXGN AxoGen, Inc. Buy 8.17% 3.95%
INSM Insmed Incorporated Buy 8.75% 11.34%
NUTX Nutex Health Inc. Buy 9.46% 20.31%
ACRS Aclaris Therapeutics, Inc. Buy 8.18% 4%
MD Pediatrix Medical Group, Inc. Buy 7.54% 0%
MDXG MiMedx Group, Inc. Buy 7.81% 3.63%
NVRO Nevro Corp. Buy 8.32% 10.38%
LGND Ligand Pharmaceuticals Incorporated Buy 8.02% 6.42%
AXSM Axsome Therapeutics, Inc. Buy 7.73% 2.59%
CERS Cerus Corporation Buy 7.54% 0%
DNLI Denali Therapeutics Inc. Buy 8.08% 7.16%
ATXS Astria Therapeutics, Inc. Buy 7.32% -2.82%
ORGO Organogenesis Holdings Inc. Buy 6.91% 6.01%
AGEN Agenus Inc. Buy 6.42% 0%
TGTX TG Therapeutics, Inc. Sell -3.83% -6.64%
FATE Fate Therapeutics, Inc. Sell -2.69% 24.57%
ORMP Oramed Pharmaceuticals Inc. Sell -3.44% 3.36%
VKTX Viking Therapeutics, Inc. Sell -3.03% 16.38%
AVXL Anavex Life Sciences Corp. Sell -3.76% 6.64%
EBS Emergent BioSolutions Inc. Sell -4.37% -8.61%
GERN Geron Corporation Sell -3.86% -0.68%
MDRX Allscripts Healthcare Solutions, Inc. Sell -5.03% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • MDRX
  • AGEN
Assets Removed
Asset Action Perf %
APLS Buy All -9.8%
TNDM Sell All -5.5%
Assets Rebalanced
None
2025-01-17 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 5.88% 0.47%
BLUE bluebird bio, Inc. Buy 4.87% -16.73%
AORT Artivion, Inc. Buy 6.56% 3.34%
ESPR Esperion Therapeutics, Inc. Buy 7.03% -3.42%
AXGN AxoGen, Inc. Buy 8.1% 0.99%
INSM Insmed Incorporated Buy 8.47% 5.54%
NUTX Nutex Health Inc. Buy 9.5% 18.31%
ACRS Aclaris Therapeutics, Inc. Buy 8.07% 0.4%
MD Pediatrix Medical Group, Inc. Buy 7.57% -1.64%
MDXG MiMedx Group, Inc. Buy 7.92% 2.95%
NVRO Nevro Corp. Buy 8.17% 6.13%
LGND Ligand Pharmaceuticals Incorporated Buy 7.75% 0.73%
AXSM Axsome Therapeutics, Inc. Buy 7.69% -0.06%
CERS Cerus Corporation Buy 7.57% -1.62%
DNLI Denali Therapeutics Inc. Buy 7.76% 0.79%
ATXS Astria Therapeutics, Inc. Buy 7.66% -0.51%
ORGO Organogenesis Holdings Inc. Buy 6.66% 0%
TGTX TG Therapeutics, Inc. Sell -3.81% -4.07%
FATE Fate Therapeutics, Inc. Sell -2.6% 28.57%
ORMP Oramed Pharmaceuticals Inc. Sell -3.54% 2.52%
APLS Apellis Pharmaceuticals, Inc. Sell -4% -8.35%
VKTX Viking Therapeutics, Inc. Sell -3.06% 17.17%
AVXL Anavex Life Sciences Corp. Sell -3.96% 3.79%
EBS Emergent BioSolutions Inc. Sell -4.36% -5.95%
GERN Geron Corporation Sell -3.89% 0.68%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • ORGO
Assets Removed
Asset Action Perf %
MDRX Sell All -6.56%
Assets Rebalanced
None
2025-01-16 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 5.82% -3.76%
BLUE bluebird bio, Inc. Buy 5.05% -16.43%
MDRX Allscripts Healthcare Solutions, Inc. Buy 6.02% -4.51%
AORT Artivion, Inc. Buy 6.53% -0.56%
ESPR Esperion Therapeutics, Inc. Buy 7.11% -5.56%
AXGN AxoGen, Inc. Buy 8.51% 2.63%
INSM Insmed Incorporated Buy 8.45% 1.84%
NUTX Nutex Health Inc. Buy 8.49% 2.16%
ACRS Aclaris Therapeutics, Inc. Buy 8.34% 0.4%
MD Pediatrix Medical Group, Inc. Buy 7.96% 0%
MDXG MiMedx Group, Inc. Buy 7.96% 0%
NVRO Nevro Corp. Buy 7.96% 0%
LGND Ligand Pharmaceuticals Incorporated Buy 7.96% 0%
AXSM Axsome Therapeutics, Inc. Buy 7.96% 0%
CERS Cerus Corporation Buy 7.96% 0%
DNLI Denali Therapeutics Inc. Buy 7.96% 0%
ATXS Astria Therapeutics, Inc. Buy 7.96% 0%
TGTX TG Therapeutics, Inc. Sell -4.08% -7.79%
FATE Fate Therapeutics, Inc. Sell -2.84% 24.57%
ORMP Oramed Pharmaceuticals Inc. Sell -3.69% 1.68%
APLS Apellis Pharmaceuticals, Inc. Sell -4.04% -5.79%
VKTX Viking Therapeutics, Inc. Sell -3.39% 11.32%
AVXL Anavex Life Sciences Corp. Sell -4.57% -7.39%
EBS Emergent BioSolutions Inc. Sell -4.3% -1.17%
GERN Geron Corporation Sell -4.14% -2.38%
The percentage of cash held in the portfolio is: 3.07%
New Assets Added
  • MD
  • MDXG
  • NVRO
  • LGND
  • AXSM
  • CERS
  • DNLI
  • ATXS
Assets Removed
Asset Action Perf %
ARDX Sell All 0.19%
Assets Rebalanced
None
2025-01-15 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 5.78% -4.19%
BLUE bluebird bio, Inc. Buy 4.87% -19.25%
MDRX Allscripts Healthcare Solutions, Inc. Buy 5.86% -6.67%
AORT Artivion, Inc. Buy 6.43% -1.82%
ARDX Ardelyx, Inc. Buy 6.89% 5.24%
ESPR Esperion Therapeutics, Inc. Buy 7.18% -4.27%
AXGN AxoGen, Inc. Buy 8.27% -0.05%
INSM Insmed Incorporated Buy 8.19% -0.93%
NUTX Nutex Health Inc. Buy 8.28% 0%
ACRS Aclaris Therapeutics, Inc. Buy 8.28% 0%
TGTX TG Therapeutics, Inc. Sell -4.01% -6.21%
FATE Fate Therapeutics, Inc. Sell -2.68% 28.57%
ORMP Oramed Pharmaceuticals Inc. Sell -3.71% 0.84%
APLS Apellis Pharmaceuticals, Inc. Sell -3.84% -0.91%
VKTX Viking Therapeutics, Inc. Sell -3.29% 13.69%
AVXL Anavex Life Sciences Corp. Sell -4.21% 0.76%
EBS Emergent BioSolutions Inc. Sell -4.22% 0.53%
GERN Geron Corporation Sell -4.03% 0%
The percentage of cash held in the portfolio is: 59.97%
New Assets Added
  • GERN
  • NUTX
  • ACRS
Assets Removed
Asset Action Perf %
NUTX Buy All -3.63%
Assets Rebalanced
None
2025-01-14 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 5.8% -3.07%
BLUE bluebird bio, Inc. Buy 5.12% -14.42%
MDRX Allscripts Healthcare Solutions, Inc. Buy 6.07% -2.56%
AORT Artivion, Inc. Buy 6.31% -2.94%
ARDX Ardelyx, Inc. Buy 7.16% 10.11%
ESPR Esperion Therapeutics, Inc. Buy 7.25% -2.56%
AXGN AxoGen, Inc. Buy 8.21% 0%
INSM Insmed Incorporated Buy 8.21% 0%
TGTX TG Therapeutics, Inc. Sell -3.71% 1.18%
FATE Fate Therapeutics, Inc. Sell -2.75% 26.29%
ORMP Oramed Pharmaceuticals Inc. Sell -3.69% 0.84%
NUTX Nutex Health Inc. Sell -3.77% 0.39%
APLS Apellis Pharmaceuticals, Inc. Sell -3.94% -4.19%
VKTX Viking Therapeutics, Inc. Sell -3.74% 1.09%
AVXL Anavex Life Sciences Corp. Sell -4.21% 0%
EBS Emergent BioSolutions Inc. Sell -4.21% 0%
The percentage of cash held in the portfolio is: 75.87%
New Assets Added
  • AVXL
  • EBS
  • AXGN
  • INSM
Assets Removed
None
Assets Rebalanced
None
2025-01-13 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 5.84% -3.63%
BLUE bluebird bio, Inc. Buy 5.17% -14.72%
MDRX Allscripts Healthcare Solutions, Inc. Buy 6.15% -2.46%
AORT Artivion, Inc. Buy 6.5% -1.16%
ARDX Ardelyx, Inc. Buy 6.25% -5.06%
ESPR Esperion Therapeutics, Inc. Buy 7.54% 0%
TGTX TG Therapeutics, Inc. Sell -3.91% -3.14%
FATE Fate Therapeutics, Inc. Sell -3.17% 16%
ORMP Oramed Pharmaceuticals Inc. Sell -3.78% -0.42%
NUTX Nutex Health Inc. Sell -3.83% 0%
APLS Apellis Pharmaceuticals, Inc. Sell -3.83% 0%
VKTX Viking Therapeutics, Inc. Sell -3.83% 0%
The percentage of cash held in the portfolio is: 84.9%
New Assets Added
  • NUTX
  • APLS
  • VKTX
  • ESPR
Assets Removed
None
Assets Rebalanced
None
2025-01-09 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 6.06% 0.36%
BLUE bluebird bio, Inc. Buy 5.15% -14.72%
MDRX Allscripts Healthcare Solutions, Inc. Buy 6.14% -2.46%
AORT Artivion, Inc. Buy 6.56% 0%
ARDX Ardelyx, Inc. Buy 6.56% 0%
TGTX TG Therapeutics, Inc. Sell -3.89% -2.75%
FATE Fate Therapeutics, Inc. Sell -3.59% 4.57%
ORMP Oramed Pharmaceuticals Inc. Sell -3.75% 0%
The percentage of cash held in the portfolio is: 80.75%
New Assets Added
  • ORMP
  • AORT
  • ARDX
Assets Removed
None
Assets Rebalanced
None
2025-01-08 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 5.97% -0.82%
BLUE bluebird bio, Inc. Buy 5.47% -9.07%
MDRX Allscripts Healthcare Solutions, Inc. Buy 6.27% 0%
TGTX TG Therapeutics, Inc. Sell -3.77% 0%
FATE Fate Therapeutics, Inc. Sell -3.75% 0%
The percentage of cash held in the portfolio is: 89.8%
New Assets Added
  • FATE
  • MDRX
Assets Removed
None
Assets Rebalanced
None
2025-01-07 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 5.99% 0%
BLUE bluebird bio, Inc. Buy 5.99% 0%
TGTX TG Therapeutics, Inc. Sell -3.75% 0%
The percentage of cash held in the portfolio is: 91.78%
New Assets Added
  • TGTX
  • TNDM
  • BLUE
Assets Removed
None
Assets Rebalanced
None
2024-12-26 00:00:00 : Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is: 100%
New Assets Added
None
Assets Removed
Asset Action Perf %
PCRX Sell All NA
Assets Rebalanced
None
2024-12-25 00:00:00 : Portfolio change date
Asset Action Weight PnL
PCRX Pacira BioSciences, Inc. Buy 7.99% 1.99%
The percentage of cash held in the portfolio is: 92.01%
New Assets Added
None
Assets Removed
Asset Action Perf %
CUTR Buy All 19.51%
ATEC Buy All 7.7%
NKTR Buy All 14.95%
Assets Rebalanced
None
2024-12-24 00:00:00 : Portfolio change date
Asset Action Weight PnL
PCRX Pacira BioSciences, Inc. Buy 7.88% 0.58%
CUTR Cutera, Inc. Sell -3.37% 19.51%
ATEC Alphatec Holdings, Inc. Sell -3.81% 8.8%
NKTR Nektar Therapeutics Sell -3.52% 15.89%
The percentage of cash held in the portfolio is: 102.82%
New Assets Added
None
Assets Removed
Asset Action Perf %
FATE Buy All 43.92%
Assets Rebalanced
None
2024-12-23 00:00:00 : Portfolio change date
Asset Action Weight PnL
PCRX Pacira BioSciences, Inc. Buy 7.84% -0.58%
FATE Fate Therapeutics, Inc. Sell -2.18% 43.24%
CUTR Cutera, Inc. Sell -3.7% 12.2%
ATEC Alphatec Holdings, Inc. Sell -3.94% 6.5%
NKTR Nektar Therapeutics Sell -3.66% 13.08%
The percentage of cash held in the portfolio is: 105.63%
New Assets Added
None
Assets Removed
Asset Action Perf %
IBRX Buy All 48.02%
Assets Rebalanced
None
2024-12-20 00:00:00 : Portfolio change date
Asset Action Weight PnL
PCRX Pacira BioSciences, Inc. Buy 8.05% 2.51%
IBRX ImmunityBio, Inc. Sell -2.04% 47.02%
FATE Fate Therapeutics, Inc. Sell -2.15% 43.92%
CUTR Cutera, Inc. Sell -3.58% 14.63%
ATEC Alphatec Holdings, Inc. Sell -3.71% 11.5%
NKTR Nektar Therapeutics Sell -3.68% 12.15%
The percentage of cash held in the portfolio is: 107.1%
New Assets Added
None
Assets Removed
Asset Action Perf %
CARA Buy All -49.27%
Assets Rebalanced
None
2024-12-19 00:00:00 : Portfolio change date
Asset Action Weight PnL
PCRX Pacira BioSciences, Inc. Buy 7.77% 0.52%
IBRX ImmunityBio, Inc. Sell -1.99% 47.42%
FATE Fate Therapeutics, Inc. Sell -2.15% 42.91%
CUTR Cutera, Inc. Sell -3.72% 9.76%
ATEC Alphatec Holdings, Inc. Sell -3.64% 11.8%
NKTR Nektar Therapeutics Sell -3.58% 13.08%
CARA Cara Therapeutics, Inc. Sell -3.34% 4.38%
The percentage of cash held in the portfolio is: 110.66%
New Assets Added
None
Assets Removed
Asset Action Perf %
SEM Buy All 10.17%
Assets Rebalanced
None
2024-12-18 00:00:00 : Portfolio change date
Asset Action Weight PnL
PCRX Pacira BioSciences, Inc. Buy 8.07% 3.88%
SEM Select Medical Holdings Corporation Sell -3.14% 6.04%
IBRX ImmunityBio, Inc. Sell -2.14% 43.85%
FATE Fate Therapeutics, Inc. Sell -2.41% 36.49%
CUTR Cutera, Inc. Sell -3.54% 14.63%
ATEC Alphatec Holdings, Inc. Sell -3.95% 4.8%
NKTR Nektar Therapeutics Sell -3.95% 4.67%
CARA Cara Therapeutics, Inc. Sell -3.2% 8.76%
The percentage of cash held in the portfolio is: 114.26%
New Assets Added
None
Assets Removed
Asset Action Perf %
APLS Sell All 5.82%
MGNX Sell All -1.76%
Assets Rebalanced
None
2024-12-12 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 5.88% 4.2%
MGNX MacroGenics, Inc. Buy 5.66% 0.29%
PCRX Pacira BioSciences, Inc. Buy 8.35% 6.5%
SEM Select Medical Holdings Corporation Sell -3.26% 3.29%
IBRX ImmunityBio, Inc. Sell -2.4% 37.5%
FATE Fate Therapeutics, Inc. Sell -2.82% 26.35%
CUTR Cutera, Inc. Sell -3.67% 12.2%
ATEC Alphatec Holdings, Inc. Sell -4.05% 3.1%
NKTR Nektar Therapeutics Sell -3.99% 4.67%
CARA Cara Therapeutics, Inc. Sell -3.45% 2.55%
The percentage of cash held in the portfolio is: 103.75%
New Assets Added
None
Assets Removed
Asset Action Perf %
ESPR Sell All -13.23%
Assets Rebalanced
None

Load more previous compositions

Compositions In The Last 2W Compositions In The Last 1M Compositions In The Last 3M Compositions In The Last 6M

Market Overview

Disclaimer Quantam Research does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, assets forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
Cookies Settings